Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 9Daunorubicin 7Etoposide 6Methotrexate 5Idarubicin 5Thioguanine 4Mitoxantrone 4Cyclophosphamide 4Hydrocortisone 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Asparaginase 3Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2ON 01910 2Mycophenolic Acid 2Dexamethasone 2Busulfan 2zosuquidar trihydrochloride 1valspodar 1tipifarnib 1sargramostim 1palmitoyl-L-asparaginase 1merphos 1lonafarnib 1hydrocortisone hemisuccinate 1fludarabine phosphate 1fludarabine 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anemia, Refractory, with Excess of Blasts × lonafarnib × Clear all
NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 3 Terminated
47 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡